Filing Analysis
Dyadic International received notification from Nasdaq that it has initiated delisting proceedings due to failures to meet the minimum bid price of $1.00 and continued listing standards. The company intends to request a hearing to stay the delisting and seek an extension to regain compliance.
🚩 Red Flags
- Multiple listing rule violations (Bid Price and Continued Listing Standards).
- Lack of sufficient shareholders' equity ($< $5M) to automatically qualify for a bid price extension.
- Explicit reference to the risk of being unable to 'continue to operate as a going concern' if delisted.
📋 Key Facts
- Received delisting notification from Nasdaq on June 18, 2026.
- Failed to maintain minimum bid price of $1.00 per share (Rule 5450(a)(1)).
- Failed to meet the $5 million shareholders' equity requirement for a bid price extension.
- Failed to meet Continued Listing Standards (Rule 5550(b)), which requires $2.5M equity, $35M market value, or $500k net income.
- Company plans to request a hearing before an independent Nasdaq panel to stay the delisting.
- Maximum compliance extension possible through December 15, 2026.
Dyadic International, Inc. issued a press release on June 15, 2026, highlighting increased interest in its C1 Biomanufacturing Platform, specifically citing Ebola preparedness activities and growing commercial adoption.
📋 Key Facts
- The company issued a press release titled 'Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption'.
- The filing date is June 15, 2026.
- The information was furnished under Item 7.01 (Regulation FD Disclosure), meaning it is not officially 'filed' for Section 18 liability purposes.
Dyadic International, Inc. announced a collaboration with Scripps Research to develop rapid-response Hantavirus antibodies and vaccines, leveraging Dyadic's C1 platform and prior research on Andes, Marburg, and Ebola viruses.
📋 Key Facts
- Collaboration partner: Scripps Research
- Focus: Rapid-response Hantavirus antibody and vaccine development
- Technology used: Dyadic's C1 Platform for biologic production
- Date of announcement: May 28, 2026
Dyadic International, Inc. (DYAI) announced its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished under Item 2.02 of Form 8-K.
📋 Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The press release was issued on May 13, 2026.
- The report was signed by CEO Mark A. Emalfarb.
- The information is furnished under Item 2.02 and is not deemed 'filed' for Section 18 purposes.
Dyadic International received a Nasdaq deficiency notice on March 27, 2026, for failing to meet the minimum stockholders' equity, market value, or net income requirements. This represents a second active listing deficiency for the company, which is already non-compliant with the $1.00 minimum bid price rule.
🚩 Red Flags
- Multiple concurrent Nasdaq listing deficiencies (financial standards and bid price).
- Stock price is below the $1.00 minimum requirement.
- Failure to meet any of the three alternative financial requirements for continued listing.
- Risk of delisting if compliance plans are not accepted or executed successfully.
📋 Key Facts
- Received Nasdaq deficiency notice on March 27, 2026, regarding Rule 5550(b).
- Company failed to maintain $2.5 million in stockholders' equity, $35 million in market value, or $500,000 in net income.
- The company has 45 calendar days (until May 11, 2026) to submit a plan to regain compliance.
- A separate deficiency regarding the $1.00 minimum bid price (Rule 5550(a)(2)) is already active with a June 17, 2026 deadline.
- If a compliance plan is accepted, the company may receive a cure period until September 23, 2026.
Dyadic International, Inc. announced its financial results for the full fiscal year ended December 31, 2025, via a press release on March 25, 2026.
📋 Key Facts
- The filing reports financial results for the fiscal year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was included as Exhibit 99.1.
- The report was signed by CEO Mark A. Emalfarb on March 25, 2026.
Dyadic International, Inc. entered into an At-The-Market (ATM) Issuance Sales Agreement with Craig-Hallum Capital Group LLC to sell up to $4,237,818 of its common stock. The sales will be made from time to time at prevailing market prices to provide the company with flexible access to capital.
🚩 Red Flags
- Potential dilution of existing shareholders as shares are sold into the open market.
📋 Key Facts
- Entered into an ATM Sales Agreement with Craig-Hallum Capital Group LLC on March 6, 2026.
- The company may sell shares of common stock with an aggregate offering price of up to $4,237,818.
- Sales agent will receive a commission of up to 3.0% of gross sales proceeds.
- The offering is conducted under an existing Form S-3 registration statement (File No. 333-273829) effective since August 25, 2023.